Cannabidiol and Emotional Stimuli
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 35 |
| Updated: | 2/11/2017 |
| Start Date: | February 2013 |
| End Date: | March 2017 |
Effects of Cannabidiol on Responses to Emotional Stimuli
The purpose of this research is to examine the effect of cannabidiol (CBD), a cannabinoid
compound found in marijuana, on responses to emotional stimuli. Both preclinical and
clinical studies indicate that CBD may act to reduce anxiety without excessive sedative
side-effects. Thus the investigators hypothesize that CBD may reduce responses specifically
to negative emotional and social stimuli, including pictures and emotional faces, without
altering responses to positive stimuli. To examine this, the investigators will administer
placebo, 300mg, 600mg, and 900mg CBD to healthy normal adults in a double-blind
within-subjects study. The investigators will measure subjective and subtle physical
responses to positive and negative stimuli using measures that have been characterized with
classic anxiety-reducing drugs and drugs of abuse. Further, the investigators will examine
whether CBD-induced changes in these measures of emotional response relate to changes in
actual behavior in a controlled social interaction. These results will allow the
investigators to examine the potential usefulness of CBD as an anxiety-reducing drug, and
suggest mechanisms by which CBD may reduce anxiety.
compound found in marijuana, on responses to emotional stimuli. Both preclinical and
clinical studies indicate that CBD may act to reduce anxiety without excessive sedative
side-effects. Thus the investigators hypothesize that CBD may reduce responses specifically
to negative emotional and social stimuli, including pictures and emotional faces, without
altering responses to positive stimuli. To examine this, the investigators will administer
placebo, 300mg, 600mg, and 900mg CBD to healthy normal adults in a double-blind
within-subjects study. The investigators will measure subjective and subtle physical
responses to positive and negative stimuli using measures that have been characterized with
classic anxiety-reducing drugs and drugs of abuse. Further, the investigators will examine
whether CBD-induced changes in these measures of emotional response relate to changes in
actual behavior in a controlled social interaction. These results will allow the
investigators to examine the potential usefulness of CBD as an anxiety-reducing drug, and
suggest mechanisms by which CBD may reduce anxiety.
Inclusion Criteria:
- 18-35 years of age.
- 38 healthy volunteers (19 male, 19 female; age range 18-35 years)
- All participants recruited without regard to race, religion or ethnicity through
posters, advertisements and word-of-mouth referrals.
- Candidates screened in accordance with our general screening protocol, approved by
the IRB under Protocol #13681B, which includes a physical, EKG, psychiatric screening
interview and detailed drug use history questionnaire.
Exclusion Criteria:
- Individuals with a medical condition contraindicating study participation, as
determined by the study site physician.
- Individuals regularly using any medications aside from hormonal contraception in
women.
- Individuals with a current (active in the past year) DSM-IV Axis I mood, anxiety,
eating, or substance dependence disorder or a lifetime history of a psychotic
disorder or mania.
- Women who are pregnant, nursing, or planning to become pregnant in the next 3 months
- Participants reporting a known or suspected allergy to cannabinoids.
- The self-report questionnaires the investigators use require fluency in English, and
have not been translated and validated in other languages, thus individuals with less
than a high-school education or those not fluent in English were excluded, as lack of
English familiarity at a high school level may compromise our ability to interpret
their self-reports.
- Individuals with a BMI below 19 or above 30, as this would change dosing
requirements.
- Individuals who report using marijuana >100 times in their lifetime, to reduce
variation in possible developed tolerance to CBD.
We found this trial at
1
site
University of Chicago One of the world's premier academic and research institutions, the University of...
Click here to add this to my saved trials
